FDA Oncology Announcements

VEGFR inhibitor × Gastrointestinal × Clear all

7 Announcements

FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET

Drug: Cabometyx (cabozantinib) · VEGFR inhibitor
Conditions: EndocrineGastrointestinal

FDA approves fruquintinib in refractory metastatic colorectal cancer

Trials: FRESCO-2, FRESCO
Drug: Fruzaqla (fruquintinib) · VEGFR inhibitor
Condition: Gastrointestinal

FDA approves cabozantinib for hepatocellular carcinoma

Trial: CELESTIAL
Drug: CABOMETYX (cabozantinib) · VEGFR inhibitor
Condition: Gastrointestinal

Sorafenib (NEXAVAR)

Drug: NEXAVAR tablets (sorafenib) · VEGFR inhibitor
Conditions: EndocrineGastrointestinalGenitourinary

Ziv-Aflibercept

Drug: Zaltrap (ziv-aflibercept) · VEGFR inhibitor
Condition: Gastrointestinal

Sunitinib

Drug: Sutent Capsules (sunitinib) · VEGFR inhibitor
Conditions: EndocrineGastrointestinalNET

Sorafenib

Drug: Nexavar (sorafenib) · VEGFR inhibitor
Conditions: GastrointestinalGenitourinary